ID
45332
Beskrivning
Principal Investigator: Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000554 Exome sequencing of matched pairs of tumor / normal genomic DNA was performed from high risk localized prostate cancer or lethal, metastatic, castrate resistant prostate cancer (CRPC). Exome libraries were prepared using Illumina Paired_End Genome DNA Sample Prep Kit and captured using Agilent SureSelect Capture Library or Roche EZ Exome capture library. Sequencing was performed on Illumina GAII and HiSeq 2000 platforms in paired end mde, with 80 base pair reads from the final library fragments. Copy number alterations and somatic mutations were identified.
Länk
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000554
Nyckelord
Versioner (2)
- 2022-10-31 2022-10-31 - Simon Heim
- 2022-12-13 2022-12-13 - Kristina Keller
Rättsinnehavare
Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA
Uppladdad den
31 oktober 2022
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000554 Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, age, ERG gene rearrangement in tumor, ETV1 gene rearrangement in tumor, SPINK1 gene outlier over-expression in tumor, SPINK1 gene outlier over-expression in tumor of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID and GEO accession of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of samples, histological type of samples, tumor Gleason score of sample, serum PSA, type of tumor treatment, survival in months after diagnosis, survival in months after first hormone therapy, survival in months after first chemotherapy, alias name of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
Similar models
Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, age, ERG gene rearrangement in tumor, ETV1 gene rearrangement in tumor, SPINK1 gene outlier over-expression in tumor, SPINK1 gene outlier over-expression in tumor of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID and GEO accession of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of samples, histological type of samples, tumor Gleason score of sample, serum PSA, type of tumor treatment, survival in months after diagnosis, survival in months after first hormone therapy, survival in months after first chemotherapy, alias name of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
C1257890 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,3])
Inga kommentarer